News >

Olaparib/Abiraterone Improves PFS in mCRPC

Jason M. Broderick @jasoncology
Published: Wednesday, Jun 06, 2018

Noel Clarke, MBBS, FRCS, ChM

Noel Clarke, MBBS, FRCS, ChM
Combining the PARP inhibitor olaparib (Lynparza) with the antiandrogen agent abiraterone acetate (Zytiga) reduced the risk of disease progression or death by 35% compared with abiraterone alone in pretreated patients with metastatic castration-resistant prostate cancer (mCRPC), according to phase II data presented at the 2018 ASCO Annual Meeting. 

The median progression-free survival (PFS) was 13.8 months with the combination compared with 8.2 months with single-agent abiraterone (HR, 0.65; 95% CI, 0.44-0.97; P = .034). 

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication